LEK+国际制药企业的中国市场机遇-英-24页_1mb

China Market Opportunities for International Pharmas

1. Introduction

• Market Overview: China's pharmaceutical market is the world’s second-largest, featuring a massive population, unmet clinical needs, and improving regulatory environment. International pharmas have invested over $20 billion, introduced hundreds of innovative drugs, and trained technical talent.
• Recent Trends: Chinese firms are advancing from generics to global R&D leadership, enabling partnerships and innovation hubs for international companies.

2. Strategic Opportunities

• Market Drivers: China offers a large patient base, regulated environment, and increasingly favorable policies for innovation and market access.
• Global Integration: China serves as a critical innovation hub, with accelerated drug approvals (e.g., NMPA expedited reviews, fast conditional approvals). Companies like Roche and Novartis emphasize China’s R&D and commercial potential.

3. MNC Pharmas: Adapting to the New Normal

• Accelerated Market Access: New policies allow faster global launches into China (e.g., NMPA joining ICH, expanded IMCTs).
• Pricing & Reimbursement:
  • NRDL Negotiations: Mandatory price cuts (50%-60%) for NRDL inclusion, with follow-up negotiations every two years.
  • Volume-Based Procurement (VBP): 60-80% price cuts for generic drugs, discouraging major MNC investments in certain areas.
• Product Lifecycle Shift: Post-approval growth accelerated by NRDL boosts, but revenues decline faster due to generics and VBP.
• Digital Transformation: Increased focus on digital tools for commercialization due to reduced sales rep access and VBP cost pressures.

4. New Entrants: Options & Trade-offs

• Entry Strategies:
  • Acquisition: Established access with existing infrastructure (e.g., Menarini, CSL).
  • Greenfield: Building from scratch, cost-effective but time-intensive.
  • Joint Venture (JV): Balances control and local expertise but faces cultural integration challenges.
  • Out-Licensing: Limited investment, ideal for startups, though risks from IP concerns or partner capability.
• Selection Criteria: Prioritize upfront capital, clinical trial competence, commercial experience, and IP protections for local partners.

5. Partnership Considerations

• Partner Types:
  • Local Companies: Efficient operations but potential regulatory/IP risks.
  • International Pharmas: Stronger safety/risk perception but fewer early-stage deals.
• Market Dynamics: China-to-international deals surged (e.g., BeiGene’s $2.9 billion deal with Novartis), reflecting global confidence in Chinese innovation while macroeconomic pressures may delay some partnerships.

6. Conclusion

• Key Takeaways: China remains a pivotal market for international pharmas due to its scale, regulatory openness, and innovation potential. However, companies must adapt to rapid policy changes (e.g., pricing reforms) and strategically navigate partnerships to mitigate risks. The market’s resilience and evolving ecosystem call for continued engagement and flexibility.